Overview

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression.
Phase:
Phase 3
Details
Lead Sponsor:
Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Collaborator:
Sunovion
Treatments:
Lurasidone Hydrochloride